SR
Therapeutic Areas
Alivexis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MDI-0151 (MOD-A) | Neutrophil-driven inflammatory diseases (e.g., ANCA-associated vasculitis, COPD) | Preclinical |
| MDI-0238 (MOD-B) | Mast cell-mediated diseases (e.g., chronic urticaria, anaphylaxis) | Preclinical |
| MDI-0355 (MOD-C) | Cancer (PARG inhibitor, various types) | Preclinical |
| MOD-D (WDR5 Inhibitor) | Cancer | Preclinical |